Antiangiogenic antibody BD0801 combined with immune checkpoint inhibitors achieves synergistic antitumor activity and affects the tumor microenvironment

Liting Xue(Simcere Pharmaceutical (China)), Wenqing Yang(Guangzhou University of Chinese Medicine)
BMC Cancer
October 22, 2021
Cited by 21


Related Papers